Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
ACADEMIA
Japan Hypertension Society to Retract Diovan Paper on VART Study
The Japanese Society of Hypertension will retract the main paper of one of the now discredited Diovan (valsartan) studies after its lead investigator finally conceded saying that corrections requested by the society cannot be made with remaining data at hand.…
To read the full story
Related Article
- Japan Hypertension Society to Soon Report VART Paper Retraction in Publication
September 26, 2016
- British Medical Journal Retracts Sub-Analysis Paper of VART Study
December 11, 2014
- Prof. Komuro to Issue Objection to Chiba University in Wake of Second Retraction Request Related to VART Study
September 9, 2014
- Chiba Univ. Once Again Advises Authors to Withdraw Papers from VART Study
August 19, 2014
- Chiba University Weighs Asking University of Tokyo to Punish VART Chief Investigator
July 16, 2014
- Chiba Univ. Finds Dropout Rates of 60-80% in Secondary Endpoints, Raps VART Study as “Absolutely Unreliable”
July 16, 2014
- Chiba Univ. Advises Authors to Withdraw VART Papers
May 26, 2014
- Claims of Superior Cardiorenal Protective Effects of Diovan “Cannot Be Supported”: Outside Investigation of VART Study
April 30, 2014
- Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
- MHLW Panel Concludes Novartis Systematically Involved in Diovan Trials: Report
March 28, 2014
ACADEMIA
- Refusal to See Patients due to Kostaive Shots Might Violate “Duty of Care”: Lawyer
December 17, 2024
- Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
December 6, 2024
- Consortium on Pediatric Drug Development Up and Running from This Fiscal Year
November 25, 2024
- Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan
November 8, 2024
- Alzheimer’s-Related Guidelines Being Revised to Accommodate Kisunla, Rexulti
November 6, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…